Overview

Eribulin in Advanced Solitary Fibrous Tumor

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Phase II study on advanced Solitary Fibrous Tumor (SFT) treated with eribulin
Phase:
Phase 2
Details
Lead Sponsor:
Italian Sarcoma Group
Collaborator:
Eisai Inc.